STAT3 and glioblastoma: The presence of GSCs and oncogene delivery features of exosomes [5], together with aberrations of CDK6/mTOR/STAT3 oncogenic pathways, concomitantly contribute to aggressive phenotypes and the failure of therapeutic strategies against GBM [25].